To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
March 16, 2009 > Gene expression signature discovered for metastatic prostate cancer
A team of researchers led by Phillip G. Febbo, MD (Damon Runyon-Lilly Clinical Investigator '05-'10) of Duke University, Durham, reported the discovery of a gene expression “signature” that may predict therapeutic response of men with a type of metastatic prostate cancer (called hormone refractory or castration resistant). This genomic signature is currently being tested in clinical trials for its potential to help individualize and improve therapy for these patients. Elahe A. Mostaghel, MD, PhD (Damon Runyon-Genentech Clinical Investigator '08-'11) of the Fred Hutchinson Cancer Research Center, Seattle, also contributed to this study.